Patents Assigned to THE NEW YORK STEM CELL FOUNDATION
-
Publication number: 20240054761Abstract: The present disclosure provides a system and method for image analysis which utilize trained neural networks. The system and method are useful for generation and/or analysis of a variety of objects, such as biological cells to determine clonality.Type: ApplicationFiled: October 2, 2020Publication date: February 15, 2024Applicants: New York Stem Cell Foundation, Inc., New York Stem Cell Foundation, Inc.Inventors: Brodie Fischbacher, Daniel John Paull, Zhongwei Wang
-
Patent number: 11814648Abstract: Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to O4+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, O4+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.Type: GrantFiled: June 3, 2020Date of Patent: November 14, 2023Assignee: New York Stem Cell Foundation, Inc.Inventors: Valentina Fossati, Panagiotis Douvaras
-
Patent number: 11732242Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells.Type: GrantFiled: March 5, 2021Date of Patent: August 22, 2023Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan L. Solomon
-
Patent number: 11542465Abstract: This invention concerns an integrated microfluidic system that utilizes microfluidic chip technology to receive a patient sample including cells, expand the cells, reprogram the expanded cells and then store the reprogrammed cells in a microfluidic chip. These microfluidic chips with stored reprogrammed cells may then be used in scenarios of genetic differentiation into specific cell types. Overall this system and workflow is suitable as a hospital based device that will allow the generation of iPSCs from every patient for downstream diagnostic or therapeutic use.Type: GrantFiled: November 17, 2017Date of Patent: January 3, 2023Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Stephen Chang
-
Patent number: 11471285Abstract: In some embodiments, the present invention provides tissue grafts, such as vascularized bone grafts, and methods for preparing and using such tissue grafts. In some embodiments the tissue grafts are made using pluripotent stem cells, such as autologous pluripotent stem cells. In some embodiments, the tissue grafts are made by creating a digital model of a tissue portion to be replaced or repaired, such as a bone defect, partitioning the model into two or more model segments, and then producing tissue graft segments having a size and shape corresponding to that of the model segments. Such tissue graft segments may be assembled to form a tissue graft having a size and shape corresponding to that of the tissue portion to be replaced or repaired.Type: GrantFiled: December 29, 2014Date of Patent: October 18, 2022Assignee: New York Stem Cell Foundation, Inc.Inventor: Giuseppe Maria De Peppo
-
Patent number: 11357890Abstract: The present invention provides customized hybrid bone-implant grafts and a method of manufacture thereof.Type: GrantFiled: March 31, 2017Date of Patent: June 14, 2022Assignee: New York Stem Cell Foundation, Inc.Inventors: Giuseppe Maria de Peppo, Martina Sladkova
-
Patent number: 11149250Abstract: The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.Type: GrantFiled: March 3, 2017Date of Patent: October 19, 2021Assignee: New York Stem Cell Foundation, Inc.Inventors: Panagiotis Douvaras, Scott Noggle, Stephen Chang, Valentina Fossati
-
Patent number: 11136556Abstract: The present invention provides various improved systems and methods for obtaining, generating, culturing, and handling cells, such as stem cells (including induced pluripotent stem cells or iPSCs) and differentiated cells, as well as cells and cell panels produced using such systems and methods, and uses of such cells and cell panels.Type: GrantFiled: September 30, 2019Date of Patent: October 5, 2021Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Kevin Eggan, Stephen Chang, Susan Solomon
-
Patent number: 10968435Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells.Type: GrantFiled: April 29, 2019Date of Patent: April 6, 2021Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan L. Solomon
-
Patent number: 10961503Abstract: Haploid human embryonic stem cells and cell lines, haploid multipotent human cells, and haploid differentiated human cells are provided. In addition, methods of making and using the haploid human cells are provided.Type: GrantFiled: July 28, 2016Date of Patent: March 30, 2021Assignees: New York Stem Cell Foundation, Inc., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Dietrich M. Egli, Nissim Benvenisty, Ido Sagi
-
Patent number: 10947562Abstract: The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (“IVF”) procedures.Type: GrantFiled: July 12, 2019Date of Patent: March 16, 2021Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli
-
Patent number: 10889800Abstract: The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.Type: GrantFiled: May 25, 2018Date of Patent: January 12, 2021Assignees: New York Stem Cell Foundation, Inc., Icahn School of Medicine at Mount SinaiInventors: Scott Noggle, Maitane Ortiz-Virumbrales, Sam Gandy, Ilya Kruglikov, Michelle Ehrlich
-
Patent number: 10676716Abstract: Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to O4+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, O4+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.Type: GrantFiled: May 6, 2019Date of Patent: June 9, 2020Assignee: New York Stem Cell Foundation, Inc.Inventors: Valentina Fossati, Panagiotis Douvaras
-
Patent number: 10513709Abstract: The present invention provides methods for making reconstructed diploid human oocytes comprising the diploid genome of a human somatic cell, and also methods for making human nuclear transfer embryos, human embryonic stem cells, and human differentiated cells therefrom. The present invention also provides reconstructed human oocytes, human nuclear transfer embryos, human embryonic stem cells, and differentiated cells made using such methods, as well as compositions and kits useful in performing such methods.Type: GrantFiled: February 13, 2018Date of Patent: December 24, 2019Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli
-
Patent number: 10428309Abstract: The present invention provides various improved systems and methods for obtaining, generating, culturing, and handling cells, such as stem cells (including induced pluripotent stem cells or iPSCs) and differentiated cells, as well as cells and cell panels produced using such systems and methods, and uses of such cells and cell panels.Type: GrantFiled: June 27, 2014Date of Patent: October 1, 2019Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Kevin Eggan, Stephen Chang, Susan Solomon
-
Patent number: 10351876Abstract: The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (“IVF”) procedures.Type: GrantFiled: August 31, 2016Date of Patent: July 16, 2019Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli
-
Patent number: 10301592Abstract: Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+progenitors, and then to 04+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP+mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.Type: GrantFiled: May 22, 2015Date of Patent: May 28, 2019Assignee: New York Stem Cell Foundation, Inc.Inventors: Valentina Fossati, Panagiotis Douvaras
-
Patent number: 10273459Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells. The invention system is useful for isolating somatic cells from tissue samples, producing iPSC lines from adult differentiated cells by reprogramming such cells, identifying the pluripotent reprogrammed adult cells among other cells, and expanding and screening the identified reprogrammed cells.Type: GrantFiled: November 30, 2012Date of Patent: April 30, 2019Assignee: New York Stem Cell FoundationInventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan Solomon
-
Patent number: 10214714Abstract: In some embodiments the present invention provides perfusion bioreactors and cell culture scaffolds suitable for the preparation of tissue grafts, such as bone tissue grafts. In some embodiments, the perfusion bioreactors comprise a graft chamber and/or a graft chamber insert configured to hold a tissue graft having a certain shape and/or certain dimensions, and/or to allow culture of such tissue grafts under press-fit direct perfusion conditions. In some embodiments, the perfusion bioreactors comprise an equilibration chamber.Type: GrantFiled: December 4, 2015Date of Patent: February 26, 2019Assignee: New York Stem Cell Foundation, Inc.Inventor: Giuseppe Maria de Peppo
-
Patent number: 9896699Abstract: The present invention provides methods for making reconstructed diploid human oocytes comprising the diploid genome of a human somatic cell, and also methods for making human nuclear transfer embryos, human embryonic stem cells, and human differentiated cells therefrom. The present invention also provides reconstructed human oocytes, human nuclear transfer embryos, human embryonic stem cells, and differentiated cells made using such methods, as well as compositions and kits useful in performing such methods.Type: GrantFiled: March 14, 2014Date of Patent: February 20, 2018Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli